Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Open in API
Filings indexed 130 across all filing types
Latest filing 2025-05-26 Regulatory Filings
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 60% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the issuer’s CFO under Canadian NI 52-109, certifying the interim financial report and interim MD&A for the quarter ended March 31, 2025. It is not the interim report itself (IR) nor an announcement of a report (RPA); rather, it is a required regulatory certification form. Since no specific category covers certification forms, the appropriate fallback is “Regulatory Filings” (RNS).
2025-05-26 English
Interim MD&A - English.pdf
Management Reports Classification · 92% confidence The provided text is titled “Management’s Discussion and Analysis” for the three months ended March 31, 2025 and contains narrative explanations of financial results, business developments, forward-looking statements, and regulatory updates. It is not a standalone earnings release, proxy, or full financial statements but is the MD&A section accompanying an interim financial reporting period. This corresponds to the Management Reports category (MDA).
2025-05-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive set of unaudited condensed interim consolidated financial statements for Thiogenesis Therapeutics, Corp. for the three-month period ended March 31, 2025. It includes the Statement of Financial Position, Statement of Operations and Other Comprehensive Loss, Statement of Changes in Shareholders' Equity, Statement of Cash Flows, and detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2025-05-26 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing a corporate consulting and investor relations agreement rather than financial results, a board or senior management change, dividend notice, or a formal report. It does not present quarterly or annual financial statements, regulatory filings such as 10-K, or call transcripts. It is a general corporate news announcement that does not fit any specific category but is filed as a regulatory news service release. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2025-02-20 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing that Thiogenesis Therapeutics’ shares have begun trading on the OTCQX market in the U.S. It includes corporate communication on trading venue and DTC eligibility, with no financial results, no AGM materials, no regulatory report attached, and no change in capital structure per se. This falls under the general category of miscellaneous regulatory announcements. Therefore, it is classified as a Regulatory Filing (RNS).
2025-02-12 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing that the company received final EMA clearance to initiate its Phase 2 clinical trial. It is not an earnings release, financial report, or presentation, nor does it involve dividends, share issues, M&A, or management changes. It is a general regulatory announcement regarding clinical trial approval, which does not fit any specialized category, making “Regulatory Filings (RNS)” the appropriate fallback.
2025-01-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.